A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

This study is testing IOV-3001, an experimental drug, given alongside lifileucel (a type of cell therapy using your own immune cells) for patients with advanced melanoma (skin cancer) that has stopped responding to prior immunotherapy. **You may be eligible if...** - You are 18 or older - You have unresectable or metastatic melanoma (not from the eye) that progressed during or after PD-1/PD-L1 immunotherapy - If your melanoma has the BRAF V600 mutation, you have also received or declined BRAF-targeted therapy - You have good performance status (ECOG 0–1) and life expectancy over 6 months **You may NOT be eligible if...** - You have active autoimmune disease requiring systemic treatment - You have untreated brain metastases - Your organs are not functioning well enough - You have not progressed on prior immunotherapy Talk to your doctor to see if this trial is right for you.